ArticleBioPsychoSocial medicine2025
Validation of single and combined screening tools for the detection of poststroke mood disorders in acute stroke patients in Singapore.
Article in BioPsychoSocial medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveScreening tools such as the Patient Healthcare Questionnaire (PHQ) and Hospital Anxiety and Depression Scale (HADS) are useful for detecting poststroke depression (PSD). However, validation of these tools has yet to be conducted in the Singapore stroke population.
methodA total of 138 adults were administered the HADS and both two- and nine-item versions of the PHQ. Receiver operating characteristic (ROC) analyses were utilized to validate these scales against the gold standard diagnosis of PSD through the Structured Clinical Interview for DSM-IV (SCID-IV).
resultsAll the tools examined in this study had good convergent validity (rs = 0.55-0.89) and discriminative power (Area Under Curve: 0.849-0.887). The optimal cut-off scores were ≥ 7 for the HADS depression and anxiety subscales, ≥ 10 for the total score, ≥ 2 for the PHQ-2 and ≥ 8 for the PHQ-9. Additional analyses suggest that the use of both the PHQ and the HADS in specific combinations further improved diagnostic performance.
conclusionBoth the PHQ and the HADS are acceptable tools for screening for poststroke depression in Singaporean inpatient rehabilitation care settings. Furthermore, our findings lead us to recommend using PHQ-9 with HADS-A for superior screening performance at sensitivity = 83.33%, specificity = 88.33%, positive predictive value = 51.72%, and negative predictive value = 97.25%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.